User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Primary tabs

download
  • Open access
  • PDF
  • 2.18 M
Houot, Roch Cartron, Guillaume Bijou, Fontanet de Guibert, Sophie Salles, Gilles A Van Den Neste, Eric [UCL] André, Marc [UCL] Morschhauser, Franck

(eng) The combination of rituximab and lenalidomide previously demonstrated promising efficacy in patients with aggressive non-Hodgkin lymphomas (aNHL), including diffuse large B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Here, we evaluated the combination of Obinutuzumab, a type-II anti-CD20 antibody, with lenalidomide (GALEN regimen) in patients with relapsed/refractory (R/R) aNHL. A total of 85 patients (71 DLBCL and 13 MCL) received both study drugs. The overall response (OR) at the end of induction was 35.2% for DLBCL and 46.2% for MCL patients. With a median follow-up of 2.5 years, the median PFS and OS were 4.1 months and 10.6 months for DLBCL, and 5.8 months and not reached for MCL, respectively. Subgroup analysis based on cell of origin showed that efficacy of the GALEN regimen tended to be better in ABC-DLBCL compared to GC12 DLBCL with an OR of 44.4% vs 23.1%, and a median OS of 27 months vs 7.9 months. Most common grade 3 and 4 adverse events were neutropenia (50.0%) and thrombocytopenia (13.6%). Overall, the chemo-free GALEN regimen may represent an option in some subsets of patients with R/R aggressive lymphoma

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès mixte
Publication date 2019
Language Anglais
Journal information "Leukemia" - Vol. 33, no. 3, p. 776-780 (2019)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 0887-6924
e-issn 1476-5551
Publication status Publié
Affiliations UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique
UCL - (SLuc) Service d'hématologie
UCL - (MGD) Service d'hématologie
Links
  1. Czuczman Myron S., Trněný Marek, Davies Andrew, Rule Simon, Linton Kim M., Wagner-Johnston Nina, Gascoyne Randy D., Slack Graham W., Brousset Pierre, Eberhard David A., Hernandez-Ilizaliturri Francisco J., Salles Gilles, Witzig Thomas E., Zinzani Pier Luigi, Wright George W., Staudt Louis M., Yang Yandan, Williams P. Mickey, Lih Chih-Jian, Russo Jacqueline, Thakurta Anjan, Hagner Patrick, Fustier Pierre, Song Dale, Lewis Ian D., A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, 10.1158/1078-0432.ccr-16-2818
  2. Witzig T. E., Vose J. M., Zinzani P. L., Reeder C. B., Buckstein R., Polikoff J. A., Bouabdallah R., Haioun C., Tilly H., Guo P., Pietronigro D., Ervin-Haynes A. L., Czuczman M. S., An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, 10.1093/annonc/mdq626
  3. Trněný Marek, Lamy Thierry, Walewski Jan, Belada David, Mayer Jiri, Radford John, Jurczak Wojciech, Morschhauser Franck, Alexeeva Julia, Rule Simon, Afanasyev Boris, Kaplanov Kamil, Thyss Antoine, Kuzmin Alexej, Voloshin Sergey, Kuliczkowski Kazimierz, Giza Agnieszka, Milpied Noel, Stelitano Caterina, Marks Reinhard, Trümper Lorenz, Biyukov Tsvetan, Patturajan Meera, Bravo Marie-Laure Casadebaig, Arcaini Luca, Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial, 10.1016/s1470-2045(15)00559-8
  4. Arcaini Luca, Lamy Thierry, Walewski Jan, Belada David, Mayer Jiri, Radford John, Jurczak Wojciech, Morschhauser Franck, Alexeeva Julia, Rule Simon, Cabeçadas José, Campo Elias, Pileri Stefano A., Biyukov Tsvetan, Patturajan Meera, Casadebaig Bravo Marie-Laure, Trnĕný Marek, , Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma, 10.1111/bjh.15025
  5. Morschhauser Franck Andre, Cartron Guillaume, Thieblemont Catherine, Solal-Céligny Philippe, Haioun Corinne, Bouabdallah Reda, Feugier Pierre, Bouabdallah Krimo, Asikanius Elina, Lei Guiyuan, Wenger Michael, Wassner-Fritsch Elisabeth, Salles Gilles Andre, Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study, 10.1200/jco.2012.46.9585
  6. Leonard John P., Jung Sin-Ho, Johnson Jeffrey, Pitcher Brandelyn N., Bartlett Nancy L., Blum Kristie A., Czuczman Myron, Giguere Jeffrey K., Cheson Bruce D., Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance), 10.1200/jco.2014.59.9258
  7. Martin P, Jung S -H, Pitcher B, Bartlett N L, Blum K A, Shea T, Hsi E D, Ruan J, Smith S E, Leonard J P, Cheson B D, A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance), 10.1093/annonc/mdx496
  8. Wang Michael, Fayad Luis, Wagner-Bartak Nicolaus, Zhang Liang, Hagemeister Fredrick, Neelapu Sattva S, Samaniego Felipe, McLaughlin Peter, Fanale Michelle, Younes Anas, Cabanillas Fernando, Fowler Nathan, Newberry Kate J, Sun Luhong, Young Ken H, Champlin Richard, Kwak Larry, Feng Lei, Badillo Maria, Bejarano Maria, Hartig Kimberly, Chen Wendy, Chen Yiming, Byrne Catriona, Bell Neda, Zeldis Jerome, Romaguera Jorge, Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial, 10.1016/s1470-2045(12)70200-0
  9. Ruan Jia, Martin Peter, Shah Bijal, Schuster Stephen J., Smith Sonali M., Furman Richard R., Christos Paul, Rodriguez Amelyn, Svoboda Jakub, Lewis Jessica, Katz Orel, Coleman Morton, Leonard John P., Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma, 10.1056/nejmoa1505237
  10. Zinzani Pier Luigi, Pellegrini Cinzia, Gandolfi Letizia, Stefoni Vittorio, Quirini Federica, Derenzini Enrico, Broccoli Alessandro, Argnani Lisa, Pileri Stefano, Baccarani Michele, Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial, 10.1016/j.clml.2011.02.001
  11. Ivanov Vadim, Coso Diane, Chetaille Bruno, Esterni Benjamin, Olive Daniel, Aurran-Schleinitz Therese, Schiano Jean Marc, Stoppa Anne-Marie, Broussais-Guillaumot Florence, Blaise Didier, Bouabdallah Reda, Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, 10.3109/10428194.2014.889822
  12. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu S S, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry K J, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young K H, Champlin R, Kwak L, Fayad L, Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial, 10.1038/leu.2013.95
  13. Zinzani P. L., Pellegrini C., Argnani L., Broccoli A., Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab, 10.3324/haematol.2016.147256
  14. Morschhauser Franck, Salles Gilles, Le Gouill Steven, Tilly Herve, Thieblemont Catherine, Bouabdallah Krimo, Fabiani Bettina, Ménard Cédric, Tarte Karin, Cartron Guillaume, Houot Roch, An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma, 10.1182/blood-2018-05-853499
  15. Cheson Bruce D., Horning Sandra J., Coiffier Bertr, Shipp Margaret A., Fisher Richard I., Connors Joseph M., Lister T. Andrew, Vose Julie, Grillo-López Antonio, Hagenbeek Anton, Cabanillas Fernando, Klippensten Donald, Hiddemann Wolfgang, Castellino Ronald, Harris Nancy L., Armitage James O., Carter William, Hoppe Richard, Canellos George P., Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, 10.1200/jco.1999.17.4.1244
  16. Crump Michael, Neelapu Sattva S., Farooq Umar, Van Den Neste Eric, Kuruvilla John, Westin Jason, Link Brian K., Hay Annette, Cerhan James R., Zhu Liting, Boussetta Sami, Feng Lei, Maurer Matthew J., Navale Lynn, Wiezorek Jeff, Go William Y., Gisselbrecht Christian, Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study, 10.1182/blood-2017-03-769620
  17. Vitolo Umberto, Trněný Marek, Belada David, Burke John M., Carella Angelo Michele, Chua Neil, Abrisqueta Pau, Demeter Judit, Flinn Ian, Hong Xiaonan, Kim Won Seog, Pinto Antonio, Shi Yuan-Kai, Tatsumi Yoichi, Oestergaard Mikkel Z., Wenger Michael, Fingerle-Rowson Günter, Catalani Olivier, Nielsen Tina, Martelli Maurizio, Sehn Laurie H., Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma, 10.1200/jco.2017.73.3402
Bibliographic reference Houot, Roch ; Cartron, Guillaume ; Bijou, Fontanet ; de Guibert, Sophie ; Salles, Gilles A ; et. al. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.. In: Leukemia, Vol. 33, no. 3, p. 776-780 (2019)
Permanent URL http://hdl.handle.net/2078.1/204080